Question & AnswerQ&A (DDB BOARD REGULATION NO. 1)
Under Section 36(a) Article VIII of R.A. 6425, as amended, the Dangerous Drugs Board has the power to regulate, including the exclusion or inclusion of certain drugs in the list of regulated drugs.
Board Regulation No. 1, series of 1978, provides for the temporary exclusion of Mogadon tablets from the list of regulated drugs for a period of one year, subject to certain conditions.
Mogadon tablets must be dispensed through an ordinary prescription as required under R.A. 3720 (Food, Drug and Cosmetic Act). The prescription must include the name, address, number of Privilege Tax Receipt and Opium License of the prescribing physician as well as the name and address of the patient.
After the one-year extension, Mogadon tablets automatically revert to the category of a regulated drug unless the Dangerous Drugs Board further extends this exclusion.
Yes, the period may be sooner terminated upon receipt of proof that Mogadon tablets are being abused.
The prescription requirements are governed by R.A. 3720, also known as the Food, Drug and Cosmetic Act.
Dr. Clemente S. Gatmaitan, M.D., M.P.H., the Chairman of the Dangerous Drugs Board, signed the regulation.
The regulation became effective on January 20, 1978.
The prescription must indicate the number of the prescribing physician's Privilege Tax Receipt and Opium License, along with the patient's name and address.
The Dangerous Drugs Board regulates the controlled substances under laws like R.A. 6425, but prescriptions during exclusion periods must comply with R.A. 3720, which regulates the dispensation of drugs through ordinary prescriptions.